An official website of the United States government
Covid-19 outbreak represents an exceptional test of the flexibility and the efficiency of patient medical records transfer among healthcare providers which ended up in boundless interruption to the healthcare industry. This public crisis has pushed for an urgent innovation of the patient medical records transference (PMRT) system to meet the needs and provide appropriate patient care. Moreover, the drawback effects of Covid-19 changed the healthcare system forever, more patients are requesting more control, secure, and smoother experience when they want access to their health records. However, the problems stem from the lack of interoperability among the healthcare system and providers and the added burden of cyber-attacks on an already stressed system call for an immediate solution. In this work, we present a secured blockchain framework that ensures patients full ownership over their medical data which can be stored in their private IPFS and later can be shared with an authorized provider. The analysis of the proposed security and privacy aspects shows promising results in providing time savings and resulted in enhanced confidentiality and less disruption in patient-provider interactions.
more »
« less
Open data on industry payments to healthcare providers reveal potential hidden costs to the public
Abstract Healthcare industry players make payments to medical providers for non-research expenses. While these payments may pose conflicts of interest, their relationship with overall healthcare costs remains largely unknown. In this study, we linked Open Payments data on providers’ industry payments with Medicare data on healthcare costs. We investigated 374,766 providers’ industry payments and healthcare costs. We demonstrate that providers receiving higher amounts of industry payments tend to bill higher drug and medical costs. Specifically, we find that a 10% increase in industry payments is associated with 1.3% higher medical and 1.8% higher drug costs. For a typical provider, for example, a 10% or $25 increase in annual industry payments would be associated with approximately $1,100 higher medical costs and $100 higher drug costs. Furthermore, the association between payments and healthcare costs varies markedly across states and correlates with political leaning, being stronger in more conservative states.
more »
« less
- Award ID(s):
- 1916518
- PAR ID:
- 10154029
- Publisher / Repository:
- Nature Publishing Group
- Date Published:
- Journal Name:
- Nature Communications
- Volume:
- 10
- Issue:
- 1
- ISSN:
- 2041-1723
- Format(s):
- Medium: X
- Sponsoring Org:
- National Science Foundation
More Like this
-
-
Off-label drug use is an important healthcare topic as it is quite common and sometimes inevitable in medical practice. Though gaining information about off-label drug uses could benefit a lot of healthcare stakeholders such as patients, physicians, and pharmaceutical companies, there is no such data repository of such information available. There is a desire for a systematic approach to detect off-label drug uses. Other than using data sources such as EHR and clinical notes that are provided by healthcare providers, we exploited social media data especially online health community (OHC) data to detect the off-label drug uses, with consideration of the increasing social media users and the large volume of valuable and timely user-generated contents. We adopted tensor decomposition technique, CP decomposition in this work, to deal with the sparsity and missing data problem in social media data. On the basis of tensor decomposition results, we used two approaches to identify off-label drug use candidates: (1) one is via ranking the CP decomposition resulting components, (2) the other one is applying a heterogeneous network mining method, proposed in our previous work [9], on the reconstructed dataset by CP decomposition. The first approach identified a number of significant off-label use candidates, for which we were able to conduct case studies and found medical explanations for 7 out of 12 identified off-label use candidates. The second approach achieved better performance than the previous method [9] by improving the F1-score by 3%. It demonstrated the effectiveness of performing tensor decomposition on social media data for detecting off-label drug use.more » « less
-
Patient-generated health data (PGHD), created and captured from patients via wearable devices and mobile apps, are proliferating outside of clinical settings. Examples include sleep tracking, fitness trackers, continuous glucose monitors, and RFID-enabled implants, with many additional biometric or health surveillance applications in development or envisioned. These data are included in growing stockpiles of personal health data being mined for insight via big data analytics and artificial intelligence/deep learning technologies. Governing these data resources to facilitate patient care and health research while preserving individual privacy and autonomy will be challenging, as PGHD are the least regulated domains of digitalized personal health data (U.S. Department of Health and Human Services, 2018). When patients themselves collect digitalized PGHD using “apps” provided by technology firms, these data fall outside of conventional health data regulation, such as HIPAA. Instead, PGHD are maintained primarily on the information technology infrastructure of vendors, and data are governed under the IT firm’s own privacy policies and within the firm’s intellectual property rights. Dominant narratives position these highly personal data as valuable resources to transform healthcare, stimulate innovation in medical research, and engage individuals in their health and healthcare. However, ensuring privacy, security, and equity of benefits from PGHD will be challenging. PGHD can be aggregated and, despite putative “deidentification,” be linked with other health, economic, and social data for predictive analytics. As large tech companies enter the healthcare sector (e.g., Google Health is partnering with Ascension Health to analyze the PHI of millions of people across 21 U.S. states), the lack of harmonization between regulatory regimes may render existing safeguards to preserve patient privacy and control over their PHI ineffective. While healthcare providers are bound to adhere to health privacy laws, Big Tech comes under more relaxed regulatory regimes that will facilitate monetizing PGHD. We explore three existing data protection regimes relevant to PGHD in the United States that are currently in tension with one another: federal and state health-sector laws, data use and reuse for research and innovation, and industry self-regulation by large tech companies We then identify three types of structures (organizational, regulatory, technological/algorithmic), which synergistically could help enact needed regulatory oversight while limiting the friction and economic costs of regulation. This analysis provides a starting point for further discussions and negotiations among stakeholders and regulators to do so.more » « less
-
Patient-generated health data (PGHD), created and captured from patients via wearable devices and mobile apps, are proliferating outside of clinical settings. Examples include sleep tracking, fitness trackers, continuous glucose monitors, and RFID-enabled implants, with many additional biometric or health surveillance applications in development or envisioned. These data are included in growing stockpiles of personal health data being mined for insight via big data analytics and artificial intelligence/deep learning technologies. Governing these data resources to facilitate patient care and health research while preserving individual privacy and autonomy will be challenging, as PGHD are the least regulated domains of digitalized personal health data (U.S. Department of Health and Human Services, 2018). When patients themselves collect digitalized PGHD using “apps” provided by technology firms, these data fall outside of conventional health data regulation, such as HIPAA. Instead, PGHD are maintained primarily on the information technology infrastructure of vendors, and data are governed under the IT firm’s own privacy policies and within the firm’s intellectual property rights. Dominant narratives position these highly personal data as valuable resources to transform healthcare, stimulate innovation in medical research, and engage individuals in their health and healthcare. However, ensuring privacy, security, and equity of benefits from PGHD will be challenging. PGHD can be aggregated and, despite putative “deidentification,” be linked with other health, economic, and social data for predictive analytics. As large tech companies enter the healthcare sector (e.g., Google Health is partnering with Ascension Health to analyze the PHI of millions of people across 21 U.S. states), the lack of harmonization between regulatory regimes may render existing safeguards to preserve patient privacy and control over their PHI ineffective. While healthcare providers are bound to adhere to health privacy laws, Big Tech comes under more relaxed regulatory regimes that will facilitate monetizing PGHD. We explore three existing data protection regimes relevant to PGHD in the United States that are currently in tension with one another: federal and state health-sector laws, data use and reuse for research and innovation, and industry self-regulation by large tech companies We then identify three types of structures (organizational, regulatory, technological/algorithmic), which synergistically could help enact needed regulatory oversight while limiting the friction and economic costs of regulation. This analysis provides a starting point for further discussions and negotiations among stakeholders and regulators to do so.more » « less
-
In the digital healthcare era, it is utmost important to harness medical information scattered across healthcare institutions to support in-depth data analysis. However, the boundaries of cyberinfrastructure of healthcare providers place obstacles on data sharing. In this position paper, we firstly identify the challenges of medical data sharing and management. Then we introduce the background and give a brief survey on the state-of-the-art. Finally, we conclude the paper by discussing a few possible research directions to cope with the challenges in current medical information sharing.more » « less
